Tag Archive for: Liver

Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease

/in

RTX001 is the first engineered Regenerative Macrophage Therapy (RMT) to be evaluated in humans with advanced liver fibrosis First patient has successfully cleared safety period with no serious adverse events Enrolment is now open for the study, with initial data readout expected in 2026 Edinburgh and London, UK, 3 September 2025 – Resolution Therapeutics (“Resolution” or “Company”), a […]

Read more

Resolution Therapeutics Announces New Breakthrough Clinical Data for Macrophage Cell Therapy in End Stage Liver Disease at EASL 2024

/in

MATCH Phase 2 data underscores significant potential of macrophage cell therapy treatment for advanced liver cirrhosis Resolution Therapeutics presents novel discovery platform for engineered macrophage cell therapy to enhance therapeutic efficacy Edinburgh and London, UK, 5 June 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company developing macrophage cell therapies to treat end-stage liver […]

Read more

Resolution Therapeutics Announces Upcoming Scientific Presentations at EASL Congress 2024

/in

– Late-breaking abstract on extended follow-up data from the MATCH Phase 2 trial accepted for poster presentation  – Poster presentation on new data highlighting the Company’s discovery platform to differentiate, engineer and cryopreserve macrophages for therapeutic use  Edinburgh and London, UK, 29 May 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering […]

Read more